iBB researchers have recently established an innovative xenogeneic-free platform to manufacture human mesenchymal-stromal-cell-derived extracellular vesicles (MSC-EVs) at clinically relevant numbers for therapeutic applications.

The team implemented a microcarrier-based stirred tank reactor system to continuously harvest EVs and enhance MSC-EV production yields. Supported by human platelet lysate-based supplements, this setup enables efficient MSC expansion and EV production, while preserving the cellular identity of the parental MSC. With the integration of a scalable downstream process, the platform ensures the isolation of high-purity EVs in large quantities, exhibiting the expected characteristics in terms of size, surface charge, morphology, protein markers, and effective internalization by target cells.

These findings represent an advance towards making MSC-EV-based therapies both cost-effective and accessible for widespread clinical use. See more.